<DOC>
	<DOCNO>NCT01196104</DOCNO>
	<brief_summary>This open-label , randomize , forced-titration clinical trial evaluate efficacy safety Technosphere Insulin ( TI ) Inhalation Powder combination insulin glargine versus insulin aspart combination insulin glargine subject type 2 diabetes .</brief_summary>
	<brief_title>Clinical Trial Evaluating Efficacy Safety Technosphere® Inhalation Insulin ( TI ) Inhalation Powder Using Gen2 Inhaler</brief_title>
	<detailed_description>Phase 3 clinical trial design examine efficacy safety inhale prandial TI Inhalation Powder combination basal insulin verse insulin aspart combination basal insulin subject type 2 diabetes suboptimally control current insulin regimens.This trial employ variety method intensively manage subject .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Men woman ≥ 18 ≤ 80 year age Clinical diagnosis type 2 diabetes mellitus 12 month Body mass index ( BMI ) ≤ 45 kg/m2 Glycated Hemoglobin ( HbA1c ) &gt; 6.5 % ≤ 10.0 % Treatment 1 3 Oral Antidiabetic Drugs ( OADs ) basal insulin minimum 3 month screen . Doses OADs must stable 3 month study entry Nonsmokers ( include cigarette , cigar , pipe , chew tobacco ) precede ≥ 6 month Office spirometry investigator site Forced expiratory volume 1 second ( FEV1 ) ≥ 65 % Third National Health Nutrition Examination Survey ( NHANES III ) predict Forced vital capacity ( FVC ) ≥ 65 % NHANES III predict Forced expiratory volume 1 second percentage force vital capacity ( FEV1/FVC ) ≥ low limit normal ( LLN ) Exclusion criterion : Current prior treatment prandial PreMix ( 70/30 ) insulin History insulin pump use within 6 week Visit 1 Treatment Glucagonlike Peptide ( GLP1 ) analog drug within precede 12 week Visit 1 History chronic obstructive pulmonary disease ( COPD ) , asthma , clinically important pulmonary disease ( eg , pulmonary fibrosis ) Any clinically significant radiological finding screen chest xray Use medication asthma , COPD , chronic respiratory condition Evidence serious complication diabetes ( eg , symptomatic autonomic neuropathy ) Significant cardiovascular dysfunction history within 3 month Visit 1 ( eg , congestive heart failure [ New York Heart Association { NYHA } Class III IV ] ) Serious arrhythmia , myocardial infarction , cardiac surgery , recurrent syncope , transient ischemic attack , cerebrovascular accident History pulmonary embolism deep venous thrombosis 12 month Screening ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>